{"entity":{"id":"nsclc-2","kind":"trial","name":"Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)","aka":["LIVIGNO-4"],"tldr":"A phase 2/3 trial testing Budigalimab in non-small-cell lung cancer, active and no longer recruiting.","summary":"Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) is a phase 2/3 interventional study registered as NCT06236438, led by AbbVie, and active but no longer recruiting on the registry. Official title: A Randomised, Phase 2/3 Study to Evaluate the Optimal Dose, Safety, and Efficacy of Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC). Planned enrolment is 840 participants (estimated). The study started in 2024-04-10 and primary completion is expected in 2031-10. No results have been posted on ClinicalTrials.gov.","status":"active","asOf":"2026-10-19","links":[{"label":"ClinicalTrials.gov NCT06236438","url":"https://clinicaltrials.gov/study/NCT06236438"}],"tags":["ctgov-ingest"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":["budigalimab","livmoniplimab"],"companies":["abbvie"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Registry status on 19 October 2026: Active, not recruiting (registry record last updated 19 October 2026; primary completion expected October 2031)."],"nct":"NCT06236438","phase":"2/3","setting":"A Randomized, Phase 2/3 Study to Evaluate the Optimal Dose, Safety, and Efficacy of Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)","sponsor":"AbbVie","participation":[{"nct":"NCT06236438","source":"https://clinicaltrials.gov/study/NCT06236438","fetchedAt":"2026-10-07T16:54:23.000Z","studySha256":"6a5903b3bad3df0e18ac9e3dc57c3e99c349c128d33c3dc9c0bedef4fb7f258d","overallStatus":"RECRUITING","lastUpdatePosted":"2026-09-14","leadSponsor":"AbbVie","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":840,"enrolmentType":"ESTIMATED","siteCount":61,"recruitingSiteCount":52,"countries":["Australia","Belgium","Chile","France","Israel","Japan","Netherlands","Puerto Rico","Spain","Taiwan","Turkey (Türkiye)","United States"]}],"started":"2024-04-10","startedType":"actual","enrolled":840,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nsclc-2/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"drug":[{"id":"budigalimab","kind":"drug","name":"Budigalimab","route":"/drugs/budigalimab/"},{"id":"livmoniplimab","kind":"drug","name":"Livmoniplimab","route":"/drugs/livmoniplimab/"}],"company":[{"id":"abbvie","kind":"company","name":"AbbVie (incl. ImmunoGen, Capstan)","route":"/companies/abbvie/"}]}}